Search

Your search keyword '"Wattel, Eric"' showing total 230 results

Search Constraints

Start Over You searched for: Author "Wattel, Eric" Remove constraint Author: "Wattel, Eric"
230 results on '"Wattel, Eric"'

Search Results

201. Outcome of lower-risk patients with myelodysplastic syndromes without 5q deletion after failure of erythropoiesis-stimulating agents

202. Prognostic Value of Genetic Alterations in Elderly Patients with Acute Myeloid Leukemia: A Single Institution Experience.

203. To the editor: Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort.

204. Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network.

206. Intragenic recruitment of NF-κB drives splicing modifications upon activation by the oncogene Tax of HTLV-1.

207. Lyon-University Hospital Experience with Gemtuzumab Ozogamicin Therapy in Acute Myeloid Leukemia: a 'Real-Life' Study.

208. A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure.

209. Elderly Patients (Age 70 Years or Older) With Secondary Acute Myeloid Leukemia or Acute Myeloid Leukemia Developed Concurrently to Another Malignant Disease.

210. Addition of suberoylanilide hydroxamic acid (Vorinostat) to azacitidine for patients with higher risk myelodysplastic syndromes and azacitidine failure: a phase II add-on study from the Groupe Francophone des Myelodysplasies.

211. Expression of embryonic stem cell markers in acute myeloid leukemia.

212. An miRNA-DNMT1 Axis Is Involved in Azacitidine Resistance and Predicts Survival in Higher-Risk Myelodysplastic Syndrome and Low Blast Count Acute Myeloid Leukemia.

213. Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.

214. TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML): TET2 exon 2 skipping in AML.

215. Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies .

216. Management of psychiatric complications in unrelated donor before unrelated peripheral hematopoietic stem cell collections.

217. A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents.

218. Oncogene- and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML).

219. Effect of Age on Treatment Decision-Making in Elderly Patients With Acute Myeloid Leukemia.

220. Effect of Initial Body Mass Index on Survival Outcome of Patients With Acute Leukemia: A Single-Center Retrospective Study.

221. HTLV-1 positive and negative T cells cloned from infected individuals display telomerase and telomere genes deregulation that predominate in activated but untransformed CD4+ T cells.

222. Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies.

223. Highly active antiretroviral treatment against STLV-1 infection combining reverse transcriptase and HDAC inhibitors.

224. Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL).

225. Clonal expansion of HTLV-1 infected cells depends on the CD4 versus CD8 phenotype.

226. Cell dynamics and immune response to BLV infection: a unifying model.

227. HTLV-1 propels untransformed CD4 lymphocytes into the cell cycle while protecting CD8 cells from death.

228. HTLV-I antisense transcripts initiating in the 3'LTR are alternatively spliced and polyadenylated.

229. Long-term follow-up of autologous stem cell transplantation after intensive chemotherapy in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.

230. Advanced Waldenström's macroglobulinemia: usefulness of Morel's scoring system in establishing prognosis.

Catalog

Books, media, physical & digital resources